Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Rapport Therapeutics, Inc.

Market Cap 1.83B 1.6B 1.48B 1.38B 2.59B 173B 2.64B 17.75B 6.87B 84.89B 6.86B 6.71B 295B P/E 2026 *
-11x
P/E 2027 * -8.99x
Enterprise Value 1.58B 1.39B 1.28B 1.2B 2.25B 150B 2.29B 15.39B 5.96B 73.59B 5.94B 5.82B 256B EV / Sales 2026 *
79.2x
EV / Sales 2027 * -
Free-Float
95.35%
Yield 2026 *
-
Yield 2027 * -
1 day+2.78%
1 week+0.95%
Current month-1.63%
1 month-2.15%
3 months+39.22%
6 months+26.89%
Current year+28.07%
1 week 36.46
Extreme 36.46
39.44
1 month 33.51
Extreme 33.5147
40.72
Current year 25.21
Extreme 25.21
40.92
1 year 10.85
Extreme 10.85
42.27
3 years 6.43
Extreme 6.43
42.27
5 years 6.43
Extreme 6.43
42.27
10 years 6.43
Extreme 6.43
42.27
Manager TitleAgeSince
Chief Executive Officer 48 2023-01-31
Chief Tech/Sci/R&D Officer 61 2022-12-31
Director of Finance/CFO 58 2023-10-31
Director TitleAgeSince
Director/Board Member 61 2023-08-22
Director/Board Member 48 2023-02-28
Director/Board Member 54 2022-01-31
Date Insider Type Main position Quantity % Market Cap.
06-09Free

Founder

15,200 0.0318%
06-09Free

Director

15,200 0.0318%
06-09Free

Director

15,200 0.0318%
Change 5-day change 1-year change 3-year change Capi.($)
+2.53%+0.95%+257.12% - 1.83B
+2.96%+4.21%-8.16%-2.76% 43.24B
+1.48%+6.97%+318.33%+556.35% 35.25B
+1.24%+4.25%+6.85%+53.47% 30.22B
+2.34%-4.23%+10.58%-19.84% 28.01B
-4.75%-8.29%+3.90%+13.88% 24.08B
+2.36%+1.11% - - 14.16B
+2.60%+1.15%+51.29%+109.02% 13.01B
+2.77%+4.02%+9.61%+15.31% 12.7B
+0.72%+4.49%+102.73%+92.66% 12.54B
Average +1.40%-0.72%+83.58%+102.26% 21.5B
Weighted average by Cap. +1.25%-0.72%+69.76%+118.88%

Financials

2026 *2027 *
Net sales 20M 17.57M 16.19M 15.16M 28.4M 1.89B 28.87M 194M 75.25M 930M 75.08M 73.46M 3.23B -
Net income -166M -146M -135M -126M -236M -15.76B -240M -1.62B -626M -7.73B -625M -611M -26.88B -219M -193M -178M -166M -312M -20.78B -317M -2.13B -826M -10.2B -824M -806M -35.44B
Net Debt -243M -214M -197M -184M -345M -23.05B -351M -2.36B -915M -11.31B -913M -894M -39.3B -336M -295M -272M -255M -477M -31.83B -485M -3.27B -1.26B -15.62B -1.26B -1.23B -54.28B
Logo Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for patients with focal onset seizures, primary generalized tonic-clonic seizures and bipolar mania. Additional preclinical and late-stage discovery stage programs are also underway, including chronic pain and hearing disorders.
Employees
84
Date Price Change Volume
26-06-23 US$38.86 +1.74% 100,782
26-06-22 US$38.19 +2.28% 255,445
26-06-18 US$37.34 +1.27% 355,436
26-06-17 US$36.87 -4.21% 273,472
26-06-16 US$38.49 +0.60% 157,086
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
38.19USD
Average target price
57.10USD
Spread / Average Target
+49.52%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RAPP Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!